1. What Is the Meningococcal Vaccine Market?
The Meningococcal Vaccine Market covers the conjugate and polysaccharide vaccines targeting the Neisseria meningitidis serogroups A, B, C, W, and Y. These cause the bacterial meningitis and septicaemia that progress from the initial non-specific symptoms to the life-threatening disease within 24 to 48 hours. Meningococcal vaccination programmes protect the adolescent and infant populations most vulnerable to the invasive meningococcal disease that the vaccines prevent. Meningococcal vaccines include the meningococcal ACWY conjugate vaccines that link the serogroup-specific polysaccharide to the carrier protein for T-cell-dependent immunity. Serogroup B vaccines use the protein antigen approach as serogroup B polysaccharide mimics human self-antigens and cannot be used as a vaccine antigen. The MenA conjugate vaccine developed for the African meningitis belt has achieved near-elimination of serogroup A meningococcal meningitis epidemics in the sub-Saharan African countries that introduced the vaccine. The meningococcal vaccine market is being shaped by the expansion of the ACWY conjugate vaccine use to include the serogroup C and W disease that has increased in prevalence in Europe. The meningococcal B vaccination programmes for the adolescent and university student populations address the outbreaks of serogroup B disease in the age group not covered by infant immunisation. Countries that limited MenB vaccine use to infants are adding adolescent programmes after the outbreak experience revealed the gap.
2. Meningococcal Vaccine Market Size & Forecast
3. Emerging Technologies
- MenAfriVac PsA-TT meningococcal A conjugate vaccine developed by the Meningitis Vaccine Project at USD 0.40 per dose has achieved the near-elimination of serogroup A meningococcal meningitis epidemics. The sub-Saharan African countries that introduced the vaccine between 2010 and 2016 have eliminated the epidemic curve that previously recurred every 5 to 12 years. The epidemic curve that recurred every 5 to 12 years has been eliminated by the vaccination campaign. This demonstrates the public health impact that the conjugate vaccine achieves when the campaign is implemented at scale.
- Meningococcal B vaccination programme expansion for the adolescent population followed the college meningitis B outbreaks in the United States, United Kingdom, and Australia. The outbreaks prompted off-label and outbreak-specific use of the licensed MenB vaccines before national advisory committee recommendations for broader adolescent use. The UK included MenB in its routine adolescent schedule following the outbreak experience. ACIP in the US adopted the shared clinical decision-making approach for MenB vaccination in healthy adolescents 16 to 23 years.
- Pentavalent ACWYBE meningococcal vaccine under development targets all 5 major meningococcal serogroups in a single vaccine that would simplify the meningococcal vaccination schedule. The current requirement for the separate MenB and ACWY conjugate vaccines administered in sequential doses or separate visits creates the schedule complexity that vaccine hesitancy research identifies as a barrier to complete meningococcal vaccination coverage. A single pentavalent vaccine would reduce this schedule burden significantly.
- Meningococcal vaccine surveillance uses the laboratory confirmation of the serogroup causing each invasive meningococcal disease case to provide the epidemiological evidence that national immunisation technical advisory groups use. The changing serogroup distribution in different age groups and geographic regions requires the evidence base to guide the evidence-based recommendations for serogroup-specific vaccination programmes. The surveillance infrastructure that generates this evidence is essential for the adaptive vaccine policy that the dynamic meningococcal serogroup epidemiology requires.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Pneumococcal Vaccine Market.
4. Key Market Opportunity
One of the most substantial opportunities in the Meningococcal Vaccine market is broader MenB adolescent vaccination, where expanding recommendations for universal protein-based MenB vaccination among adolescents beyond high-risk groups creates a larger addressable programme. Companies with approved MenB vaccines capture this recommendation-driven expansion. A parallel growth driver is driven by combination ABCWY vaccines that simplify vaccination schedules. As MenB recommendations broaden and combination vaccines gain approval, the addressable opportunity is expanding from targeted meningococcal immunisation toward comprehensive adolescent and travel meningococcal protection.
5. Top Companies in the Meningococcal Vaccine Market
The following organisations hold leading positions in the Meningococcal Vaccine Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Pfizer
- GSK
- Sanofi
- Serum Institute of India
- Bavarian Nordic
- Walvax Biotechnology
- Bharat Biotech
- BiomEd Therapeutics
6. Market Segmentation
The Meningococcal Vaccine Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Serogroup | A B ACWY Combined |
| By Type | Conjugate Protein-Based |
| By Programme | Adolescent Infant Travel |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Meningococcal Vaccine Market trajectory over the forecast period:
MenAfriVac USD 0.40-per-Dose Meningococcal A Conjugate Vaccine Achieving Near-Elimination of Serogroup A Epidemic Meningitis in Sub-Saharan Africa Has Demonstrated the Major Public Health Impact That an Affordable Conjugate Vaccine Can Achieve in the Endemic Region.The combination vaccine addresses the practitioner and patient burden of current adolescent meningococcal immunisation requiring separate MenACWY vaccination at ages 11-12 and 16, plus MenB vaccination at ages 16-23, creating three separate appointments contributing to schedule complexity and missed vaccination opportunities. Pfizer's Phase 3 MenABCWY clinical data demonstrating non-inferior immunogenicity to separately administered vaccines is the regulatory prerequisite for FDA approval that would enable ACIP to simplify the adolescent schedule to a two-dose programme eliminating the separate MenB series management challenge. GSK's competitive programme combining 4CMenB and MenACWY-TT aims to similarly consolidate meningococcal protection, and the regulatory and ACIP outcome will determine which manufacturer's combination vaccine establishes the commercial standard for adolescent immunisation.
Meningococcal B Vaccination Programme Expansion Following US and UK University Campus Outbreaks Has Driven MenB Adolescent Recommendations That Created the Broader Age-Group Coverage Beyond the Infant Schedule That Serogroup B Epidemiology Requires.PHE and NHS England's universal MenB vaccination programme initiated in 2015 with GSK's 4CMenB Bexsero at ages 2, 4, and 12 months achieved vaccine effectiveness of 82.9% against invasive MenB disease in the first vaccinated cohorts, transforming a landscape where serogroup B accounted for 85% of UK cases before vaccination. The US ACIP decision to offer MenB vaccination as preferred for the 16-23 year old population rather than universally recommended reflects the cost-effectiveness calculation that MenB disease risk in adolescents is sufficiently rare that universal recommendation would require vaccinating approximately 10 million teenagers annually to prevent approximately 250 cases. College students at highest MenB risk from living in close quarters with unfamiliar peers represent the population where Pfizer's Trumenba and GSK's Bexsero achieve the highest cost-effectiveness, and university-based programmes targeting first-year residential students have become the standard approach for MenB vaccination in North America.
Pentavalent ACWYBE Meningococcal Vaccine Under Development Covering All 5 Major Serogroups in a Single Product Would Simplify the Schedule That Currently Requires Separate MenB and ACWY Vaccines Administered in Sequential Visits.GSK's Menveo and Pfizer's Nimenrix MenACWY-TT demonstrate superior persistence of bactericidal antibody titres at 5 years versus MenACWY-DT in infant vaccination schedules, and TT-conjugation's more strong T-cell priming in infants has driven WHO and GAVI preference in African Meningitis Belt mass vaccination programmes. Age-specific immunological consideration in meningococcal vaccination includes infant immune immaturity requiring carrier protein-dependent T-cell help, waning adolescent immunity requiring booster doses at 16, and adult immunocompromised populations requiring PCV and meningococcal co-scheduling guidance distinct from healthy young adult immunisation. The traveller vaccination market representing adults attending Hajj, visiting sub-Saharan Africa, and Latin America meningitis belt countries generates substantial annual meningococcal demand at travel health clinics where quadrivalent coverage is mandatory for Saudi Arabia entry.
For related market intelligence, see the Vaccine Market.
8. Segmental Analysis
By serogroup, the serogroup B segment dominated the Meningococcal Vaccine Market in 2025, as Pfizer's Bexsero and GSK's Trumenba anchored adolescent immunisation programmes following the aggressive addition of B-strain coverage to national schedules, generating the largest share of meningococcal vaccine revenue.
By type, the multivalent combination segment is projected to register the highest growth rate through 2034, as Pfizer's MenABCWY combination vaccine advances to simplify adolescent immunisation schedules into a single product covering all major disease-causing serogroups.
9. Regional Analysis
Regional demand patterns across the Meningococcal Vaccine Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Meningococcal Vaccine Market in 2025, accounting for approximately 48% of global revenue, due to the US adolescent meningococcal vaccination programme and the commercial adoption of MenB vaccines following ACIP recommendations and Pfizer and GSK as market leaders. Moreover, travel and Hajj meningococcal vaccination sustains commercial demand. In addition, MenB and ACWY adolescent vaccination is mature in the US. Regional leadership is attributed to this combination of programme maturity and commercial adoption.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Meningococcal Vaccine Market through 2034, driven by expanding MenB vaccination recommendations across European countries and the Hajj travel vaccine market sustained by European Muslim travellers. The region is also witnessing combination ABCWY vaccine adoption growing. Moreover, school-based meningococcal vaccination programmes are mature and sustained. The combination of these demand drivers and recommendation expansion positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Meningococcal Vaccine Market was valued at USD 5.50 Bn in 2025 and is projected to reach USD 11.19 Bn by 2034, growing at a CAGR of 8.2% over the 2026–2034 forecast period.
The Meningococcal Vaccine Market is projected to grow at a CAGR of 8.2% from 2026 to 2034.
North America dominated the Meningococcal Vaccine Market in 2025, accounting for approximately 48% of global revenue, due to the US adolescent meningococcal vaccination programme and the commercial adoption of MenB vaccines following ACIP recommendations and Pfizer and GSK as market leaders.
The leading companies in the Meningococcal Vaccine Market include Pfizer, GSK, Sanofi, Serum Institute of India, Bavarian Nordic, Walvax Biotechnology, Bharat Biotech, BiomEd Therapeutics.
Menafrivac usd 0.40-per-dose meningococcal a conjugate vaccine achieving near-elimination of serogroup a epidemic meningitis in sub-saharan africa has demonstrated the major public health impact that an affordable conjugate vaccine can achieve in the endemic region.
By serogroup, the serogroup B segment dominated the Meningococcal Vaccine Market in 2025, as Pfizer's Bexsero and GSK's Trumenba anchored adolescent immunisation programmes following the aggressive addition of B-strain coverage to national schedules, generating the largest share of meningococcal vaccine revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.